Publications by authors named "F Maloisel"

Claim this Profile
C
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.
Gabriel Brisou, Jérôme Paillassa, Sophie Bernard, Olivier Tournilhac, Luc-Matthieu Fornecker, Frédéric Maloisel

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma).
Katell Le Dû, Adrien Chauchet, Sophie Sadot-Lebouvier, Olivier Fitoussi, Bijou Fontanet, Frédéric Maloisel

JMIR Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial Intelligence (AI) and Drug-Induced and Idiosyncratic Cytopenia: The Role of AI in Prevention, Prediction, and Patient Participation.
Emmanuel Andrès, Amir El Hassani Hajjam, Frédéric Maloisel, Maria Belén Alonso-Ortiz, Manuel Méndez-Bailón

Hematol Rep· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.
M Macro, C Hulin, L Vincent, A Charvet-Rumpler, L Benboubker, F Maloisel

Ann Hematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 Study.
Katell Le Du, Anne-Lise Septans, Frédéric Maloisel, Hélène Vanquaethem, Anna Schmitt

J Med Internet Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis